Race Oncology |
High $1.29 |
Low $1.18 |
Trades 155 |
Turnover $303,224 |
Volume 249,053 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (14-Nov) $307,828,256 (417th) |
Close (30-Jun) $1.23 |
Volume (30-Jun) 249,053 |
Shortsold (9-Nov) 19,354 (0.01%) (577th) |
|
52w High $3.79 |
52w Low $1.40 |
P/E - |
EPS -0.06 |
Zantrene Protects Mouse Hearts from Chemotherapy Damage
RAC released this announcement to the ASX on 30 June 2022, 9:17. The announcement is marked as price sensitive, and is 10 page(s) in length and 1.4MB in size.
You can view all announcements from RAC and see how they appear on a price chart on the announcements page.
At the date of this announcement, RAC was 0.000% short sold according to ASIC data. It was ranked the 677th most shorted stock on the ASX. It is now ranked as the 577th most shorted stock on the ASX with 0.010% of total shares short sold as of the latest reported data (09 November 2026).
| Other Recent Announcements from RAC | |
|---|---|
| Notification of cessation of securities - RAC | 29 June 2023, 9:54 |
| Proposed issue of securities - RAC | 29 June 2023, 9:52 |
| Initial Director's Interest Notice | 29 June 2023, 9:46 |
| Zantrene Protects Mouse Hearts from Chemotherapy Damage | 30 June 2022, 9:17 |
| Zantrene shows synergy with kinase inhibitors in melanoma | 28 June 2022, 9:07 |
| Zantrene Improves Immune Therapy Treatment of Melanoma | 22 June 2022, 9:14 |
| Zantrene data published in Cancer Research Journal | 21 June 2022, 9:23 |
If you were already registered, log in here.